MCM2 Expression in Different Molecular Subtypes of Epithelial Breast Cancers and its Association with Clinicopathological Parameters and Ki-67 Expression
MCM2 Expression in Different Molecular Subtypes of Epithelial Breast Cancers and its Association with Clinicopathological Parameters and Ki-67 Expression
Blog Article
Introduction: Breast cancer is one of the most common malignancies, with few subtypes having a more aggressive outcome and resistance to conventional therapies, Triple Negative Breast Cancers (TNBCs) being one such variant.The Ki-67 lacks reproducibility and a standardised cut-off.MCM2 (Minichromosome Maintenance 2) has role in DNA repair and replication and its role as alternate marker for prognosis has been studied in this case.
Aim: To study MCM2 expression with respect to histologic grade, stage, nodal status and molecular subtypes of 2010 chevy malibu exhaust manifold breast carcinoma.Also, to look for any correlation between Ki-67 and MCM2 expressions.Materials and Methods: A cross-sectional, observational study conducted on a group of 20 patients who underwent mastectomy in a Tertiary Care Centre, R.
G.Kar Medical College and Hospital, Kolkata, West Bengal, India, for a total duration of six months.Histologic grading, staging, nodal status was evaluated from Haematoxylin and Eosin (H&E) stained sections.
Formalin-Fixed Paraffin-Embedded (FFPE) blocks suitable for Immunohistochemistry (IHC) were selected and MCM2, Estrogen Receptor (ER), Human Epidermal Growth Factor Receptor 2 (HER2), Progesterone Receptor (PR)/neu and Ki-67 were performed.Scores given based on visual examination under light microscope.Analysis was done using IBM Statistical Package ck21501 for the Social Sciences (SPSS) version 25.
0 software.Results: Most of the subjects belonged to 41-55 years age group.Statistical significance was seen between high MCM2 and Ki67 expressions (p-value=0.
0171) and high histologic grade and TNBCs (p-value=0.009).High MCM2 and Ki-67 expressions also come with increased risk for advanced disease.
High Ki-67 is also a risk predictor for lymph node positive cases.Positive correlation was seen between MCM2 and (R)= 0.4318.
Conclusion: The MCM2 is a predictor for adverse outcomes in breast carcinoma cases.It may serve as an alternative to Ki-67 as a proliferation marker, to guide clinicians in treatment strategies.Its role as a therapeutic target in aggressive breast carcinomas may be evaluated with larger study population in the future.